Efficacy of Generic Imatinib After Switching from Original in Treatment of Patients with Chronic Myeloid Leukemia in the Republic of North Macedonia - A Single-Center Experience

被引：0
|
作者：
Dukovski, Dushko [1 ]
Trajkova, Sanja [1 ]
Stojanovska, Simona [1 ]
Ridova, Nevenka [1 ]
Panovska-Stavridis, Irina [1 ]
机构：
[1] Clin Hematol, Skopje, North Macedonia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CML; imatinib; selective tyrosine kinase inhibitor (TKI); chronic myeloid leukemia;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-104
引用
收藏
页码：S232 / S232
页数：1
相关论文
共 50 条
  • [41] Gynecomastia in a Chronic Myeloid Leukemia Patient After Switching from Imatinib to Flumatinib
    Luan, Chengxin
    Zhu, Ying
    Zhao, Hongguo
    PATIENT PREFERENCE AND ADHERENCE, 2024, 18 : 1961 - 1964
  • [42] Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India
    Phukan, Abhijit
    Mandal, Prakas Kumar
    Dolai, Tuphan K.
    ANNALS OF HEMATOLOGY, 2021, 100 (01) : 85 - 96
  • [43] Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: a single-center experience
    Frikha, R.
    Elloumi, M.
    Kamoun, H.
    LEUKEMIA RESEARCH, 2019, 85 : S66 - S66
  • [44] Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India
    Abhijit Phukan
    Prakas Kumar Mandal
    Tuphan K. Dolai
    Annals of Hematology, 2021, 100 : 85 - 96
  • [45] Efficacy and safety of imatinib treatment in elederly patients with chronic myeloid leukemia.
    Martino, B
    Vincelli, L
    Ronco, F
    Modafferi, B
    Princi, D
    Morabito, F
    Izzo, B
    Pane, F
    Nobile, F
    BLOOD, 2004, 104 (11) : 254B - 254B
  • [46] FIRST LINE TREATMENT OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH THE GENERIC FORMULATIONS OF IMATINIB MESYLATE
    Eskazan, A. E.
    Baslar, Z.
    Ayer, M.
    Kantarcioglu, B.
    Arica, D.
    Demirel, N.
    Aydin, D.
    Yalniz, F. F.
    Elverdi, T.
    Salihoglu, A.
    Ar, M. C.
    Aydin, S. Ongoren
    Aydin, Y.
    Tuzuner, N.
    Ozbek, U.
    Soysal, T.
    HAEMATOLOGICA, 2014, 99 : 330 - 331
  • [47] Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics
    窦雪琳
    China Medical Abstracts(Internal Medicine), 2020, 37 (01) : 59 - 60
  • [48] PLASMATIC LEVELS, RESPONSE AND TOLERANCE TO IMATINIB AFTER THE CHANGE OF GLIVEC TO GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
    Wojnicz, A.
    Cornago Navascues, J.
    Vaitekovich, V.
    Mba, C.
    Sola Aparicio, E.
    Steegmann Olmedillas, J. L.
    HAEMATOLOGICA, 2018, 103 : 232 - 232
  • [49] Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience
    Adattini, Josephine A.
    Gross, Annette S.
    Doo, Nicole Wong
    McLachlan, Andrew J.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (05):
  • [50] NILOTINIB IN IMATINIB RESISTANT OR INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA - SINGLE CENTRE EXPERIENCE
    Sninska, Z.
    Martisova, M.
    Slezakova, K.
    Hatalova, A.
    Demeckova, E.
    Mistrik, M.
    HAEMATOLOGICA, 2012, 97 : 541 - 542
12345